Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
29 July 2022 |
Main ID: |
NCT03375255 |
Date of registration:
|
12/12/2017 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)
|
Scientific title:
|
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment |
Date of first enrolment:
|
February 5, 2018 |
Target sample size:
|
15 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT03375255 |
Study type:
|
Interventional |
Study design:
|
Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
Phase 1
|
|
Countries of recruitment
|
Canada
|
United States
| | | | | | |
Contacts
|
Name:
|
Medical Director |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Sarepta Therapeutics, Inc. |
| | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|